Exclusive Interview: Poon Hung Fai of Sirnaomics China| RTM2025

Dr. H. Fai Poon is a distinguished leader in the biopharmaceutical industry, currently serving as the CEO of Sirnaomics. His impressive career includes founding Quacell, which was later acquired by Lepure, and holding key positions at Hisun Biopharm, Merck (SAFC), and the Roskamp Institute in the USA. Dr. Poon's academic credentials are equally notable, with a Ph.D. in Biological Chemistry from the University of Kentucky and an MBA from the University of South Florida.

With extensive experience in biological therapeutics, analytical research, bioinformatics and proteomics, Dr. Poon has over a decade of expertise in cell culture, particularly focusing on biopharmaceutical products. His scholarly contributions are substantial, having published more than 30 peer-reviewed articles and contributing to over 5 book chapters.

Dr. Poon's influence extends to the editorial realm, where he serves as the managing editor for a biomedical and pharmacology journal, and as an associate editor for the Journal of Chemistry, Biochemistry, and Molecular Biology, as well as the Journal of Bioinformatics and Biometrics. His leadership and expertise continue to drive innovation and excellence in the field of RNA therapeutics and beyond.